China’s e-commerce retail market is undergoing seemingly never-ending changes. At the same time, over recent years, many previously offline-oriented companies have begun actively exploring the e-commerce retail models appropriate to their business needs. For its part, Kangfu Zhijia Health Industry Group, a specialist in healthcare supplies and medical equipment, has significantly boosted its sales over the past 20 years by adjusting and developing its e-commerce channels.

Some Hong Kong drug manufacturers and local universities have been actively developing new proprietary Chinese medicine lately for further market expansion. A notable example is a product based on the classic “ma zi ren wan” herbal medicine formula, developed by Hong Kong Baptist University. This product completed the phase I clinical trials as a Western medicine with the approval of the US Food and Drug Administration, the trials being completed in 2024.

Hong Kong has many long-established and reputable proprietary Chinese medicine brands. With the transitional registration system for proprietary Chinese medicines ending in late June, the regulatory framework for Chinese medicine has entered a new phase. Additionally, the Mainland has implemented simplified approval procedures for the market registration of traditional proprietary Chinese medicines registered in Hong Kong, facilitating Hong Kong businesses in expanding into the Mainland market. These developments are expected to have a positive impact on Hong Kong’s proprietary Chinese medicine industry.

Hong Kong has many long-established and reputable proprietary Chinese medicine brands. With the transitional registration system for proprietary Chinese medicines ending in late June, the regulatory framework for Chinese medicine has entered a new phase. Additionally, the Mainland has implemented simplified approval procedures for the market registration of traditional proprietary Chinese medicines registered in Hong Kong, facilitating Hong Kong businesses in expanding into the Mainland market. These developments are expected to have a positive impact on Hong Kong’s proprietary Chinese medicine industry.

The U.S. Drug Enforcement Administration has issued a temporary order adopting import and export restrictions on certain benzimidazole-opioid substances.

The Food and Drug Administration continues to detain a broad range of food and other regulated products from Mainland China and Hong Kong as part of its mission to prevent the importation of food, drugs, biologics, cosmetics, medical devices and radiation-emitting electronic products that fail to meet the requirements of the Federal Food, Drug, and Cosmetic Act.

The Administrative Committee of the Guangzhou Development District and the People’s Government of the Huangpu District of Guangzhou Municipality recently issued a notice outlining certain measures to promote high-quality development in the biomedicine industry (Sui Pu Fu Gui No. 9 [2025]). These measures, collectively referred to as the “Biomedicine 3.0” policy, apply to enterprises, institutions, unincorporated organisations and other entities in the biomedicine industry, as well as individuals working in such entities, in the Guangzhou Development District and industry parks under its management (together referred to as “the District”) in compliance with relevant regulations. The measures took effect on 23 July 2025 and will remain in force for three years.

Lack of familiarity, a reluctance to experiment and even widespread mistrust are hindering the take-up of AI-enabled tech by the elderly.

Hungary has a robust academic infrastructure, particularly in university spin-offs, HandInScan Zrt. is one of them which founded in 2012. Global Sales Director Dezső Nagy and Business Development Manager Csilla Nemeth discuss the company’s evolution from a startup to an international enterprise with users in more than 30 economies, the experience of working with distributors to increase market penetration, and its future business development.

Hungary’s medical devices sector, dominated by innovative SMEs, is a key player in Europe’s MedTech industry, exporting 85% of its production, primarily to the EU. The competitiveness strategy aims to boost domestic production and sustainability while navigating EU MDR challenges. Opportunities for collaboration with Hong Kong include leveraging trade networks, regulatory expertise, and investment to enhance global market access and innovation.